Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions: Not listed
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 31 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Birmingham, Alabama • St. Petersburg, Florida • Fort Wayne, Indiana + 6 more

Conditions: Diabetic Gastroparesis
Interventions: Reglan ODT; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Epilepsy
Interventions: Levetiracetam; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn's Disease
Interventions: Certolizumab Pegol (CDP870); Biological
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more

Conditions: Restless Legs Syndrome
Interventions: Levetiracetam (Keppra); Drug
Lead sponsor: Sleep Health Centers; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Thymidine Kinase 2 Deficiency
Interventions: Observational retrospective data; Other
Lead sponsor: Zogenix MDS, Inc.; Industry
Eligibility: Not listed
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • Akron, Ohio + 1 more

Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions: Brivaracetam Film-coated tablet, Brivaracetam oral solution; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 2 Years to 26 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more

Conditions: Lennox Gastaut Syndrome
Interventions: ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo; Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 35 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 61
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more

Conditions: Chronic Pain
Interventions: Hydrocodone Bitartrate; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 50
States / cities: Phoenix, Arizona • Sierra Vista, Arizona • Little Rock, Arkansas + 44 more

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 108
States / cities: Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 12
States / cities: Palm Desert, California • Pasadena, California • Santa Maria, California + 9 more

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB PHARMA Inc. (US); Industry
Eligibility: 16 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Epratuzumab; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 791 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 49
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 44 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Sertraline, Levetiracetam, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Premenstrual Dysphoric Disorder
Interventions: Levetiracetam; Drug
Lead sponsor: Berkshire Health Systems; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Pittsfield, Massachusetts

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Participants
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Epilepsy
Interventions: Keppra XR (Levetiracetam XR); Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 16
States / cities: Dothan, Alabama • Northport, Alabama • Phoenix, Arizona + 13 more

Conditions: Epilepsy, Partial
Interventions: Seletracetam (ucb 44212); Drug
Lead sponsor: UCB S.A. - Pharma Sector; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 7
States / cities: Little Rock, Arkansas • San Francisco, California • Stanford, California + 4 more

Conditions: Chronic Idiopathic Axonal Polyneuropathy
Interventions: levetiracetam; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

UCB Cimzia Pregnancy Follow-up Study

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis

Levetiracetam for Benign Rolandic Epilepsy

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder

Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.